API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
TAR-210 is an intravesical delivery system designed to provide sustained, local release of erdafitinib into the bladder in patients with non-muscle-invasive bladder cancer (NMIBC) with select fibroblast growth factor receptor (FGFR) alterations.
Lead Product(s): Erdafitinib
Therapeutic Area: Oncology Product Name: TAR-210
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2024
Details:
Balversa (erdafitinib) is a once-daily, oral FGFR kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations.
Lead Product(s): Erdafitinib
Therapeutic Area: Oncology Product Name: Balversa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2024
Details:
TAR-210 is an intravesical delivery system designed to provide sustained, local release of erdafitinib into the bladder in patients with non-muscle-invasive bladder cancer (NMIBC) with select fibroblast growth factor receptor (FGFR) alterations.
Lead Product(s): Erdafitinib
Therapeutic Area: Oncology Product Name: TAR-210
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2023
Details:
Balversa (erdafitinib) is a once-daily, oral FGFR kinase inhibitor. It is being evaluated for the treatment of non-muscle-invasive bladder cancer with select fibroblast growth factor.
Lead Product(s): Erdafitinib
Therapeutic Area: Oncology Product Name: Balversa
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2023
Details:
BALVERSA (erdafitinib) is a once-daily, oral FGFR kinase inhibitor that is approved by the U.S. FDA and EMA for the treatment of adults with locally advanced or mUC that have susceptible FGFR3 or FGFR2 genetic alterations.
Lead Product(s): Erdafitinib
Therapeutic Area: Oncology Product Name: Balversa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2023
Details:
BALVERSA® (erdafitinib) is a once-daily, oral FGFR kinase inhibitor that is approved by the U.S. FDA for the treatment of adults with locally advanced or mUC that have susceptible FGFR3 or FGFR2 genetic alterations.
Lead Product(s): Erdafitinib
Therapeutic Area: Oncology Product Name: Balversa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
The safety profile of BALVERSA (Erdafitinib) observed in RAGNAR was consistent with the known safety profile of erdafitinib in metastatic urothelial carcinoma (mUC). Across tumor types, 44.9 percent of patients experienced adverse events of grade three or above.
Lead Product(s): Erdafitinib,Cetrelimab,Cisplatin
Therapeutic Area: Oncology Product Name: Balversa
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
The safety profile of BALVERSA® in combination with cetrelimab was generally similar to that of BALVERSA® monotherapy used in bladder cancer. With this combination of erdafitinib and cetrelimab change tumor microenvironment to make it more receptive to PD-1 intervention.
Lead Product(s): Erdafitinib,Cetrelimab
Therapeutic Area: Oncology Product Name: Balversa
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021
Details:
The preclinical derazantinib data may provide an explanation for differences in reported adverse event profiles between various FGFR kinase inhibitors. Furthermore, derazantinib shows promising efficacy in patient-derived tumor models with gene aberrations in FGFR1-3.
Lead Product(s): Derazantinib,Erdafitinib
Therapeutic Area: Oncology Product Name: ARQ 087
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020